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ABSTRACT Rifapentine is a rifamycin used to treat tuberculosis. As is the case for
rifampin, plasma exposures of rifapentine are associated with the treatment re-
sponse. While concomitant food intake and HIV infection explain part of the phar-
macokinetic variability associated with rifapentine, few studies have evaluated the
contribution of genetic polymorphisms. We evaluated the effects of functionally sig-
niﬁcant polymorphisms of the genes encoding OATP1B1, the pregnane X receptor
(PXR), constitutive androstane (CAR), and arylacetamide deacetylase (AADAC) on rifa-
pentine exposure. Two studies evaluating novel regimens among southern African
patients with drug-susceptible pulmonary tuberculosis were included in this analysis.
In the RIFAQUIN study, rifapentine was administered in the continuation phase of
antituberculosis treatment in 1,200-mg-once-weekly or 900-mg-twice-weekly doses.
In the Daily RPE study, 450 or 600 mg was given daily during the intensive phase of
treatment. Nonlinear mixed-effects modeling was used to describe the pharmacoki-
netics of rifapentine and to identify signiﬁcant covariates. A total of 1,144 drug con-
centration measurements from 326 patients were included in the analysis. Pharma-
cogenetic information was available for 162 patients. A one-compartment model
with ﬁrst-order elimination and transit compartment absorption described the data
well. In a typical patient (body weight, 56 kg; fat-free mass, 45 kg), the values of
clearance and volume of distribution were 1.33 liters/h and 25 liters, respectively. Pa-
tients carrying the AA variant (65.4%) of AADAC rs1803155 were found to have a
10.4% lower clearance. HIV-infected patients had a 21.9% lower bioavailability. Once-
weekly doses of 1,200 mg were associated with a reduced clearance (13.2%) com-
pared to that achieved with more frequently administered doses. Bioavailability was
23.3% lower among patients participating in the Daily RPE study than in those par-
ticipating in the RIFAQUIN study. This is the ﬁrst study to report the effect of AADAC
rs1803155AA on rifapentine clearance. The observed increase in exposure is modest
and unlikely to be of clinical relevance. The difference in bioavailability between the
two studies is probably related to the differences in food intake concomitant with
the dose. HIV-coinfected patients had lower rifapentine exposures.
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Rifamycins play a key role in the multidrug treatment of tuberculosis. Their sterilizingactivity is exposure dependent (1–3). Rifapentine was approved by the Food and
Drug Administration (FDA) in 1998 for the treatment of pulmonary tuberculosis (3, 4).
Rifapentine pharmacokinetics are inﬂuenced by age, weight, dosing pattern, human
immunodeﬁciency virus (HIV) infection, and sex (5, 6). Rifapentine is less rapidly
absorbed than rifampin, with peak plasma concentrations being reached within 5 h.
Concomitant food intake markedly increases its absorption; the extent of rifapentine
absorption increased by 33 to 86% when given with meals (7). Rifapentine has a half-life
of approximately 12 h in humans (8, 9). With its long half-life and excellent sterilizing
activity, rifapentine is an attractive alternative to rifampin and is increasingly used to
treat active tuberculosis and latent infection. However, there is marked interpatient
variability in rifamycin pharmacokinetics (10). The primary metabolic pathways for
rifapentine involve deacetylation to the primary enzymatic metabolite, 25-desacetyl
rifapentine, which is mediated by human arylacetamide deacetylase (AADAC), and
nonenzymatic hydrolysis, resulting in the formation of the secondary metabolites
3-formyl rifapentine and 3-formyldesacetyl rifapentine (11). The protein binding of
rifapentine is estimated to be about 98% (3, 12). Like other rifamycins, rifapentine
induces its own metabolism (9).
Previously published data indicate that single nucleotide polymorphisms (SNPs) in
the solute carrier organic anion transporter 1B1 (SLCO1B1) gene encoding the OATP1B1
transmembrane receptor affect rifampin concentrations (13, 14). The SLCO1B1
rs4149032 C T polymorphism, found in 70% of South Africans with tuberculosis living
in Cape Town, was associated with 20% and 28% reductions in rifampin bioavailability
in heterozygotes and homozygotes, respectively (14). Rifamycins are also substrates of
the drug efﬂux pump P glycoprotein, coded for by the polymorphic ABCB1 gene (15),
and are metabolized mainly by polymorphic human arylacetamide deacetylase
(AADAC) (16). Human rifamycin exposures are also modulated by the pregnane X
receptor (PXR) and constitutive androstane (CAR) nuclear receptors (17). Since the
development of resistance to rifamycins and their bactericidal effects are related to
rifamycin concentrations, SNPs substantially inﬂuencing rifamycin concentrations may
be of therapeutic importance. Little is known about the pharmacogenetic correlates of
rifapentine pharmacokinetics, which may potentially help in ﬁnding the optimal dose
of rifapentine. Therefore, the aim of this study was to determine the effect of poly-
morphisms of SLCO1B1, PXR, CAR, and AADAC on rifapentine pharmacokinetics.
RESULTS
A total of 326 patients were included in the study and contributed a total of 1,151
concentrations-time points. Only 7 concentrations were below the lower limit of
quantiﬁcation (LLOQ) and were omitted from the analysis. The median body weight
and the median age of the study participants were 56 kg and 32 years, respectively. All
demographic characteristics are summarized in Table 1.
The population pharmacokinetics of rifapentine were well described by a one-
compartment model with ﬁrst-order elimination and transit compartment absorption.
Fat-free mass (FFM) was found to be the best size descriptor for clearance (change in
the NONMEM objective function value [ΔOFV], 93 points [P 0.001] when including
FFM for allometric scaling on clearance and 23 points better than when using body
weight), and total body weight was found to be the best size descriptor for the volume
of distribution (ΔOFV, 20; P 0.001). The absorption of rifapentine was described using
a series of transit compartments, which signiﬁcantly improved the model with respect
to the use of simple ﬁrst-order absorption (ΔOFV, 421; P 0.001). In a typical patient
(FFM, 46 kg; weight, 56 kg), the values of clearance and volume of distribution were
1.33 liters/h and 25 liters, respectively. Final parameter estimates (shown in Table 2)
Francis et al. Antimicrobial Agents and Chemotherapy
April 2019 Volume 63 Issue 4 e01964-18 aac.asm.org 2
were in agreement with the previously published results (6, 18), and a visual predictive
check (VPC) of the ﬁnal model is shown in Fig. 1.
Of 326 patients, pharmacogenetic data were available for 162 (49.7%), all of whom
were enrolled from South African sites. The distribution of genotype and allele fre-
quencies are presented in Table 3. SLCO1B1 rs2306283 and AADAC rs1803155 variant
alleles were found in 82% of patients, whereas the NR1I2 rs2472677 and NR1I2
rs1523130 variant alleles existed at a low overall frequency of 33.5% and 16.4%,
respectively. In keeping with our previous ﬁndings among South Africans in Cape Town
(14), the SLCO1B1 rs4149032 variant allele frequency was found to be 0.75 (Table 3).
After screening and inclusion of genetic information (and imputation of the missing
genotype with a mixture model), patients homozygous for the AADAC rs1803155 AA
polymorphism were found to have a 10.4% lower clearance of rifapentine than subjects
that were rs1803155 GG or GA (ΔOFV, 6.2; P 0.013). Initially, the three categories of
rs1803155 (AA, GA, GG) were analyzed as separate groups to estimate the respective
effects of GA and GG. However, the estimated effects were similar for GG and GA, and
when combined, the model goodness of ﬁt (GOF) was not affected. Using the principle
of parsimony, we decided to use the simpler model, as the effects of GG and GA were
not statistically signiﬁcant. The other pharmacogenetic variants did not affect the
pharmacokinetic parameters.
Patients infected with HIV were found to have a 21.9% lower bioavailability (ΔOFV,
42; P 0.001). The patients who were treated with high 1,200-mg doses of rifapentine
tended to have clearance reduced by 13.2% compared to the clearance for the patients
in the other dose groups (ΔOFV, 17; P 0.001). The pharmacokinetic differences
between the two studies were explored, and it was found that the bioavailability of
rifapentine in the Daily RPE study was 23.3% lower than that in the RIFAQUIN study
TABLE 1 Demographic and clinical characteristics of patients
Demographic or clinical characteristic
Values for patients from the following study:
Daily RPE,
450 mg (n 44)
Daily RPE,
600 mg (n 41)
RIFAQUIN,
900 mg (n 116)
RIFAQUIN,
1,200 mg (n 125)
Overall
(n 326)
No. of samples for PKa analysis 166 130 416 432 1,144
No. of males/no. of females 33/11 32/9 72/44 81/44 218/108
No. (%) of HIV-positive patients 6 (13.6) 7 (17.1) 30 (25.9) 16(12.8) 59(18.1)
Median (range) age (yr) 29 (19–61) 29 (18–63) 31 (19–64) 34 (19– 80) 32 (18–80)
Median (range) wt (kg) 55 (45–79) 55 (45–94) 55 (38–77) 57 (38– 78) 56 (38–94)
Median (range) FFM (kg) 47 (32–58) 47 (32–56) 45 (27–62) 45 (27–60) 45 (27–62)
aPK, pharmacokinetic.
TABLE 2 Final parameter estimates for rifapentine population pharmacokinetic modela
Parameter
Estimate Variability
Value 95% CIc % CV 95% CI
CLb (liters/h) 1.33 1.14, 1.54 23.0 (IIV) 17.7, 28.6
Vb (liters) 25 21.9, 28.4 12.8 (IIV) 8.8, 17.4
ka (h1) 0.814 0.568, 1.26 48.9 (IOV) 36.4, 59.8
MTT (h) 1.47 1.20, 1.78 37.4 (IOV) 28.3, 48.6
NN 10.2 6.70, 14.0
F 1 (ﬁxed) 20.3 (IOV) 14.9, 26.4
Proportional residual error (%) 9.56 7.09, 13.2
Additive residual error (mg/liter) 0.247 0.143, 0.401
Effect of HIV on F (%) 21.9 33.2, 6.64
Effect of group on 1,200-mg dose in RIFAQUIN study on CL (%) 13.2 22.8, 4.36
Effect of Daily RPE study on F (%) 23.3 35.6, 9.25
AADAC rs1803155 (AA) effect on CL (%) 10.4 17.3, 3.53
aCL, oral clearance; V, apparent volume of distribution in the central compartment; ka, ﬁrst-order absorption rate constant; MTT, absorption mean transit time; NN,
number of hypothetical transit compartments; F, oral bioavailability; HIV, human immunodeﬁciency virus positivity; AADAC, arylacetamide deacetylase gene; IIV,
interindividual variability; IOV, interoccasion variability; CV, coefﬁcient of variation; CI, conﬁdence interval.
bThe typical values of clearance and volume of distribution reported for a patient with a body weight of 56 kg and FFM of 46 kg.
cThe 95% conﬁdence interval of parameter estimates was obtained with sampling importance resampling (SIR; n 1,000) of the ﬁnal model.
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(ΔOFV, 59; P 0.001). The pharmacogenetic covariates other than the AADAC
rs1803155 polymorphism did not have signiﬁcant effects on the pharmacokinetic
parameters.
DISCUSSION
The present study is the ﬁrst to investigate the inﬂuence of various plausible
physiologically relevant candidate gene polymorphisms on rifapentine pharmacokinet-
ics. We developed a population pharmacokinetic model of rifapentine which was
consistent with that developed in previous studies and tested the effect of genotype
information on the pharmacokinetic parameters. We showed that the AADAC rs1803155
polymorphism is associated with rifapentine clearance. Subjects carrying the AA geno-
type had a 10.4% lower clearance than those carrying AG or GG, thus leading to
increased rifapentine exposure. The low clearance due to this polymorphism is consis-
tent with the ﬁndings of previous studies reporting the decreased activity of AADAC
due to the presence of the variant allele (19). The majority of patients in our study had
the AADAC rs1803155 AA variant allele, which occurred at a frequency of 0.82, and 65%
were homozygous for the single nucleotide polymorphism, which could, in part,
account for the relatively high rifapentine exposures described. The polymorphism
occurs at lower frequencies of 0.50 to 0.64 in European American, African American,
Korean, and Japanese populations (19). Another study identiﬁed lower rifapentine
FIG 1 Visual predictive check (VPC) for the ﬁnal rifapentine population pharmacokinetic model in log scale, stratiﬁed according to the different dose groups
in the analysis. The lower, middle, and upper solid lines are the 2.5th, 50th, and 97.5th percentiles of the observed plasma concentration, respectively. The
shaded areas are the 95% conﬁdence intervals for the same percentiles, obtained from resimulations of the same trial.
TABLE 3 Observed genotype and allele frequency of single nucleotide polymorphisms in
the studya
Genotype Genotype (frequencyb) Allele (frequency)
SLCO1B1 A G rs2306283 AA (8, 4.94) AG (43, 26.5) GG (111, 68.5) A (0.18) G (0.82)
SLCO1B1 C T rs4149032 CC (15, 9.26) CT (52, 32.1) TT (95, 58.6) C (0.25) T (0.75)
NR1I2 C T rs2472677c CC (71, 44.1) CT (72, 44.7) TT (18, 11.2) C (0.67) T (0.34)
NR1I2 T C rs1523130 TT (116, 71.6) CT (39, 24.1) CC (7, 4.3) T (0.84) C (0.16)
AADAC G A rs1803155 GG (3, 1.85) GA (53, 32.7) AA (106, 65.4) G (0.18) A (0.82)
aData are for 162 patients, unless indicated otherwise.
bThe data in parentheses represent the number, percent, of patients.
cData are available only for 161 patients.
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concentrations in black Africans, but the inﬂuence of pharmacogenetic factors, which
might account for the difference in the genotype frequencies between the populations,
was not explored (20), whereas Sloan et al., who explored the inﬂuence of AADAC gene
polymorphisms on rifampin pharmacokinetics in Malawian patients, did not identify a
signiﬁcant relationship (21).The prevalence of variant genotypes is different between
African ethnic groups and may be the reason for this contrasting effect. As only 3 of 162
patients had rs1803155 GG, no meaningful separate estimate of clearance for this
genotype could be obtained. In further attempts to explain the variability in rifapentine
pharmacokinetics, we explored the effects of several polymorphisms of drug transport-
ers and transcriptional regulators. The choice of polymorphisms was based on those
previously described to affect drug disposition and also previous pharmacogenetic
studies conducted with rifampin. Interestingly, we could not detect the effect of the
SLCO1B1 rs4149032 polymorphism on the pharmacokinetics of rifapentine, even with a
carrier-no carrier approach. The frequency of SLCO1B1 in our cohort was 0.75, which is
in agreement with previous ﬁndings in South African patients from the Cape Town
region. Similarly, we did not ﬁnd a statistically signiﬁcant effect associated with
SLCO1B1 rs2306283, which existed in our study population at a frequency of 0.82.
SLCO1B1 polymorphisms have been reported to be associated with low rifampin levels
(13, 14), and the lack of an effect on rifapentine may suggest differences in the
absorption, distribution, metabolism, and excretion of the two drugs. It may be that this
transporter does not play a major role in the pharmacokinetics of rifapentine or that the
variant allele is associated with greater induction by rifampin. We did not observe an
effect due to polymorphisms of the transcriptional regulators. This could be due to the
activation of PXR or CAR by rifapentine, which may have overridden any constitutive
effects.
Additionally, we found that HIV-infected patients have a lower bioavailability of
rifapentine. While the association of HIV infection with antituberculosis drug exposures
is inconsistent, our ﬁndings for rifapentine are consistent with those from recent studies
(22–24). The data available were not sufﬁcient to identify potential interactions of
rifapentine with the various antiretroviral drugs prescribed concomitantly.
Patients in the higher-dose group (1,200 mg given once weekly) had increased
exposure in the current study, contrary to the ﬁndings of Savic et al., who described a
decrease in the bioavailability of rifapentine with increased dose (6). The reduced
dosing frequency in this group may have led to reduced autoinduction and, thus,
increased exposure.
Previous reports demonstrated that exposure to rifamycins is reduced in males due
to a higher FFM/body weight ratio (25). The study by Langdon et al. described a 35%
reduction in the clearance of 25-desacetyl rifapentine among females (5). In the present
analysis, as allometric scaling with FFM accounted for the variability associated with sex,
we did not observe any outstanding effects of sex. There was a difference in bioavail-
ability between the two studies included in this analysis. This may be due to differences
in food intake with the dose. Rifapentine absorption is strongly enhanced when it is
administered with food (7). The ﬁnding that the Daily RPE study had a lower bioavail-
ability may arise from the fact that meals with the dose were not standardized, in
contrast to the RIFAQUIN study, where a standard meal was provided throughout the
study.
To conclude, our study is the ﬁrst to show that the AADAC rs1803155 (AA) genotype
is associated with lower rifapentine clearance, leading to increased rifapentine expo-
sure. This effect should be conﬁrmed in a larger independent analysis. The pharmaco-
genetic association was modest compared to the study effect, which is likely linked to
differences in the pattern of food use across the studies and highlights the importance
of food intake recommendations both when the drug is used in a programmatic setting
and when its pharmacokinetics are investigated. Additionally, we found that rifapentine
exposure was lower in HIV-infected patients, a ﬁnding that is consistent with the
ﬁndings of previous studies and that warrants further investigation to assess whether
dose adjustment strategies should be considered. Lastly, patients dosed with 1,200-
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mg-once-weekly doses had lower clearance, possibly as a result of less pronounced
autoinduction.
MATERIALS AND METHODS
Study population. This analysis was performed on patients diagnosed with pulmonary tuberculosis
from two clinical studies: the phase III RIFAQUIN study (registration number ISRCTN44153044) (26) and
the two-stage activity-safety study of daily rifapentine (27), referred to here as the Daily RPE study
(ClinicalTrials.gov registration number NCT00814671). A subset of participants from these studies pro-
vided their consent for us to assess the effect of genetic polymorphisms of nuclear receptors, drug-
metabolizing enzymes, and drug transporters on the pharmacokinetics of rifapentine.
The RIFAQUIN study included two experimental arms in which patients were dosed with daily
moxiﬂoxacin, rifampin, pyrazinamide, and ethambutol for 2 months, followed by a continuation phase
with either 4 months of 1,200 mg rifapentine once weekly together with 400 mg moxiﬂoxacin or
2 months of 400 mg moxiﬂoxacin twice weekly with 900 mg rifapentine. The RIFAQUIN study was
conducted at sites in the Western Cape and Gauteng regions of South Africa and in Harare, Zimbabwe.
The doses of rifapentine and moxiﬂoxacin were taken with 240 ml of water 15 min after a light meal of
2 hard-boiled eggs with bread. During the 4th month of treatment, blood samples were drawn for
determination of plasma rifapentine concentrations. The pharmacokinetic assessment involved rich
sampling (with samples drawn at pre-dose and 1, 2, 3, 5, 7, 10, 12, 26, and 50 h after dosing) or sparse
sampling (with samples drawn at about 2, 5, and 24 or 48 h after dosing).
The Daily RPE study was open label and had two experimental arms. Patients with pulmonary
tuberculosis were randomized to 450 or 600 mg rifapentine daily, which replaced 600 mg rifampin during
the intensive phase of standard therapy. The study participants were recruited in the Western Cape,
South Africa. The patients were advised to take the required rifapentine dose with food, but no
standardized meal was provided during the study, and no accurate details about food intake with the
dose were recorded. Pharmacokinetic sampling was performed at approximately 1 month after starting
therapy, and samples were obtained with either intensive sampling (with samples drawn at pre-dose and
at 0.75, 1.5, 3.5, 5, 12, and 24 h after dosing) or sparse sampling (with samples drawn 0.5 to 2 h and 5 to
8 h after dosing). Separate written informed consent for the pharmacogenetic study was obtained from
participants retrospectively. The pharmacogenetic study was reviewed and approved by the Research
Ethics Committee of the University of Cape Town and the University of the Witwatersrand.
Drug determination. Plasma rifapentine concentrations were determined with a validated liquid
chromatography-tandem mass spectrometry (LC-MS/MS) assay developed in the Division of Clinical
Pharmacology, University of Cape Town. Samples were processed with a protein precipitation extraction
method using rifaximin as the internal standard, followed by high-performance liquid chromatography
with MS/MS detection using an AB Sciex API 3200 instrument. The analyte and internal standard were
monitored at mass transitions of the protonated precursor ions m/z 877.3 and m/z 786.3 to the product
ions m/z 845.4 and m/z 754.1 for rifapentine and rifaximin, respectively. The calibration curves ﬁt
quadratic (weighted by 1/concentration) regressions over the range of 0.156 to 40.0 mg/liter for
rifapentine. The accuracies for the rifapentine assay were 103.9%, 102.8%, and 97.5% at the low, medium,
and high quality control levels, respectively, during interbatch validation. The lower limit of quantiﬁca-
tion (LLOQ) was 0.156 mg/liter.
SNP genotyping. Genomic DNA was extracted from 200 l whole blood using a QIAamp DNA
minikit (Qiagen, Inc., Valencia, CA) in accordance with the manufacturer’s protocol. DNA was quantiﬁed
spectrophotometrically using a NanoDrop spectrophotometer (Thermo Fisher Scientiﬁc Inc., Wilmington,
DE) before storage at 20°C. Genotyping was performed by real-time PCR on a DNA Engine Chromo4
system (Bio-Rad Laboratories, Inc., Hercules, CA). The PCR protocol involved an initial denaturation step
at 95°C for 15 min, followed by 50 cycles of ampliﬁcation at 95°C for 15 s and a ﬁnal annealing at 60°C
for 1 min. TaqMan genotyping master mix and assays for SLCO1B1 rs2306283 (SNP identiﬁer
C_1901697_20), SLCO1B1 rs4149032 (C_1901709_10), NR1I2 rs2472677 (C_26079845_10), NR1I2
rs1523130 (C_9152783_20), and AADAC rs1803155 (C_8911003_1_) were obtained from Thermo Fisher
Scientiﬁc (Waltham, MA). Allelic discrimination plots and genotype assignments were performed using
Opticon Monitor (version 3.1) software from Bio-Rad Laboratories.
Pharmacokinetic analysis. Rifapentine plasma concentration-time data were analyzed using a
nonlinear mixed-effects model implemented in NONMEM (version 7.4.2) software (28). The execution of
runs was through the Perl-speaks-NONMEM, Pirana, and graphical diagnostics were created using Xpose
(version 4.6.0) and R software (29, 30). Estimation of typical population pharmacokinetic parameters,
along with their random interindividual variability (IIV) and interoccasion variability (IOV), was performed
using a ﬁrst-order conditional estimation method with the - interaction (FOCE INTER). A lognormal
distribution was assumed for IIV and IOV, and a combined additive and proportional model for the
residual unexplained variability (RUV) was evaluated. Various structural models including a one- or
two-compartment distribution with ﬁrst-order elimination and ﬁrst-order absorption with or without a
lag time or transit compartment absorption were tested (31). The inﬂuence of genetic polymorphisms on
the rifapentine pharmacokinetics for patients with an unknown genotype was identiﬁed using mixture
modeling (32). The effect of the genotype was ﬁrst tested using the method EXTRA, which not only
estimates the association only for patients with available genetic information but also estimates an
additional covariate effect for patients with the unknown genotype. Subsequently, the MIX method to
impute values using mixture modeling was applied to include the patient with unknown genotype to
strengthen the robustness of the ﬁndings (32). Model selection was based on changes in the NONMEM
objective function value (ΔOFV) and visual inspection of conditional weighted residuals (CWRES) versus
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time, visual predictive checks (33), and basic goodness-of-ﬁt (GOF) plots. During model development,
physiological plausibility and the precision of the parameter estimates were also considered. The model
parameters of the ﬁnal model were evaluated for their precision using the sampling importance
resampling (SIR) method (34).
Allometric scaling was applied to clearance (CL) and the volume of distribution (V) to adjust for the
effect of body size, as described by Anderson and Holford (35). Fat-free mass (FFM) and fat mass (FAT)
were tested as alternative size predictors instead of total body weight through allometric scaling (35, 36).
After the inclusion of allometric scaling, potential demographic, study site-speciﬁc, and pharmacogenetic
covariates were screened by inspecting parameter-versus-covariate plots and then tested in the model
using drops in the objective function value (which was assumed to be 2 distributed and, thus, in which
a 3.84-point drop was considered signiﬁcant at a P value of0.05 for the inclusion of a single parameter)
while scrutinizing the physiological plausibility of the effect (37).
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